Growth Metrics

Terns Pharmaceuticals (TERN) Net Cash Flow (2020 - 2023)

Terns Pharmaceuticals' Net Cash Flow history spans 4 years, with the latest figure at $41.8 million for Q4 2023.

  • For Q4 2023, Net Cash Flow fell 47.92% year-over-year to $41.8 million; the TTM value through Dec 2023 reached -$63.4 million, down 166.27%, while the annual FY2025 figure was $363.3 million, 345.38% up from the prior year.
  • Net Cash Flow reached $41.8 million in Q4 2023 per TERN's latest filing, up from -$43.0 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $80.2 million in Q4 2022 to a low of -$103.3 million in Q2 2023.
  • Average Net Cash Flow over 4 years is $4.2 million, with a median of -$1.7 million recorded in 2020.
  • The largest YoY upside for Net Cash Flow was 5181.82% in 2021 against a maximum downside of 493.0% in 2021.
  • A 4-year view of Net Cash Flow shows it stood at $61.2 million in 2020, then plummeted by 127.9% to -$17.1 million in 2021, then skyrocketed by 569.8% to $80.2 million in 2022, then crashed by 47.92% to $41.8 million in 2023.
  • Per Business Quant, the three most recent readings for TERN's Net Cash Flow are $41.8 million (Q4 2023), -$43.0 million (Q3 2023), and -$103.3 million (Q2 2023).